Newer therapies - DiabetesontheNet

Type 1 diabetes prevention and screening, hybrid closed-loop systems, principles of good peer support

Stay abreast of the latest news that could impact diabetes nursing.

3 Jan 2023

Cardiovascular and renal outcomes of glucose-lowering drugs: Updated meta-analysis

Data from 260 trials of eight drug classes highlights the benefits of metformin, SGLT2 inhibitors, GLP-1 RAs and pioglitazone.

11 Dec 2022

We got there in the end: A great step forward in type 1 diabetes care

Both technological and biological interventions have hit major milestones and are offering a step change in how we treat type 1 diabetes.

21 Nov 2022

EMPA-KIDNEY trial shows benefits of empagliflozin in CKD

Reduced risk of renal progression and cardiovascular death in a wide range of people with CKD, with eGFR as low as 20.

18 Nov 2022

The 2022 ADA/EASD consensus: Great advice if we can get past the drug shortages!

Su Down gives her take on the new ADA/EASD type 2 diabetes guidance, albeit in light of the current shortage of the weekly GLP-1 RAs.

2 Nov 2022

Latest news: FLASH-UK study, tirzepatide marketing authorisation, Dexcom G7 launch and GLP-1 RA shortages

Stay abreast of the latest news that could impact diabetes nursing.

2 Nov 2022

ADA/EASD type 2 diabetes consensus 2022: News from the 58th EASD Annual Meeting

Update to the ADA/EASD Consensus Report, a new GIP/GLP-1/glucagon receptor agonist and UKPDS 44 years on.

2 Nov 2022

PCDS consensus statement: A strategy for managing the supply shortage of the GLP-1 RAs Ozempic and Trulicity

A strategy for safely switching to alternative agents within the GLP-1 RA class if stocks are limited.

6 Oct 2022

Highlights from the 58th Annual Meeting of the European Association for the Study of Diabetes

Pam Brown summarises the key presentations from a primary care perspective.

3 Oct 2022

Journal club: My patient is on a statin. Why are they not also on an SGLT2 inhibitor?

Discussion of recent notable papers. Calculating the costs of diabetes complications, and how to reduce their risk.

5 Sep 2022

Ideas for improving patient outcomes: the quirky and the ones in the guidelines

Reviewing the latest evidence, Vinod Patel offers a number of changes that could be made to improve outcomes of people with type 2 diabetes.

18 Aug 2022

Do SGLT2 inhibitors protect against pneumonia and sepsis?

Reductions in pneumonia and sepsis, as well as death due to infection, seen with SGLT2 inhibitors versus DPP-4 inhibitors.

18 Aug 2022

Renal outcomes with SGLT2 versus DPP-4 inhibitors: CPRD data

SGLT2is are associated with a reduced risk of kidney disease progression and death compared with DPP-4is.

18 Aug 2022

Editorial: Implications of prescribing SGLT2 inhibitors to a wider population

SGLT2i licensing extensions and their implications for primary care.

12 Jul 2022

Latest news: Draft ADA/EASD advice, more data on tirzepatide, dulaglutide in paediatric T2D, and tech-assisted remission

Headlines from the American Diabetes Association 82nd Scientific Sessions, held in New Orleans and online from 3rd to 7th June.

30 Jun 2022

The evolving role of SGLT2 inhibitors

A review of SGLT2 inhibitors and their benefits beyond glucose lowering, their place in the latest guidelines, and how to use them safely and effectively.

30 Jun 2022

News in brief: Highlights of the American Diabetes Association 82nd Scientific Sessions

Key stories for primary care from the conference.

15 Jun 2022

My patient is on a statin. Why are they not also on an SGLT2 inhibitor?

Vinod Patel highlights the costs associated with diabetes complications and the savings that can be made by preventing them.

10 Jun 2022